Anna Vanazzi

767 total citations
42 papers, 352 citations indexed

About

Anna Vanazzi is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anna Vanazzi has authored 42 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pathology and Forensic Medicine, 15 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anna Vanazzi's work include Lymphoma Diagnosis and Treatment (37 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CNS Lymphoma Diagnosis and Treatment (8 papers). Anna Vanazzi is often cited by papers focused on Lymphoma Diagnosis and Treatment (37 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CNS Lymphoma Diagnosis and Treatment (8 papers). Anna Vanazzi collaborates with scholars based in Italy, Switzerland and United States. Anna Vanazzi's co-authors include Giovanni Martinelli, Giovanni Paganelli, Chiara Maria Grana, Marta Cremonesi, Mahila Ferrari, Pier Francesco Ferrucci, Mirco Bartolomei, Davide Radice, Giancarlo Pruneri and Emanuele Zucca and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Anna Vanazzi

39 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Vanazzi Italy	12	252	162	99	80	62	42	352
Manuela Arcamone Italy	8	283 1.1×	191 1.2×	47 0.5×	108 1.4×	42 0.7×	24	357
Jordina Rovira Spain	8	227 0.9×	137 0.8×	43 0.4×	89 1.1×	23 0.4×	9	310
Vittoria Tarantino Italy	6	264 1.0×	152 0.9×	119 1.2×	33 0.4×	115 1.9×	13	352
Maria Cristina Pirosa Switzerland	10	156 0.6×	119 0.7×	74 0.7×	52 0.7×	59 1.0×	28	305
Manfred Welslau Germany	7	335 1.3×	306 1.9×	49 0.5×	228 2.9×	77 1.2×	28	501
Diana Libster Israel	9	188 0.7×	115 0.7×	62 0.6×	70 0.9×	76 1.2×	16	301
Baha Alkuzweny United States	5	369 1.5×	255 1.6×	127 1.3×	184 2.3×	29 0.5×	7	459
Sabine Neser Germany	4	386 1.5×	282 1.7×	58 0.6×	200 2.5×	28 0.5×	6	435
Ursula Haak Germany	2	413 1.6×	280 1.7×	55 0.6×	229 2.9×	41 0.7×	4	448
T Beck United States	3	265 1.1×	161 1.0×	124 1.3×	149 1.9×	31 0.5×	5	388

Countries citing papers authored by Anna Vanazzi

Since Specialization

Citations

This map shows the geographic impact of Anna Vanazzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Vanazzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Vanazzi more than expected).

Fields of papers citing papers by Anna Vanazzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Vanazzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Vanazzi. The network helps show where Anna Vanazzi may publish in the future.

Co-authorship network of co-authors of Anna Vanazzi

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Vanazzi. A scholar is included among the top collaborators of Anna Vanazzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Vanazzi. Anna Vanazzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tabanelli, Valentina, Maria Rosaria Sapienza, Federica Melle, et al.. (2025). Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma. eJHaem. 6(1). e1103–e1103. 1 indexed citations

Pirosa, Maria Cristina, Sara Steffanoni, Anna Vanazzi, et al.. (2024). Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35). Hematological Oncology. 42(6). e3312–e3312. 2 indexed citations

Mazzara, Saveria, Laura Lavinia Travaini, Francesca Botta, et al.. (2023). Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL. Blood Advances. 7(4). 630–643. 6 indexed citations

Botta, Francesca, Mahila Ferrari, Sara Raimondi, et al.. (2022). The Impact of Segmentation Method and Target Lesion Selection on Radiomic Analysis of 18F-FDG PET Images in Diffuse Large B-Cell Lymphoma. Applied Sciences. 12(19). 9678–9678. 3 indexed citations

Camisaschi, Chiara, Patrizia Mancuso, Sara Trabanelli, et al.. (2022). Dampening of cytotoxic innate lymphoid cells: A new tumour immune escape mechanism in B cell non-Hodgkin's lymphoma. Cellular Immunology. 382. 104615–104615. 2 indexed citations

Garusi, Cristina, et al.. (2022). A Rare Case of BIA-ALCL Mass Associated with Mastectomy Skin Flap Erythema After Immunization with COVID-19. Aesthetic Plastic Surgery. 47(1). 116–121. 1 indexed citations

Moccia, Alden A., Christian Taverna, Sämi Schär, et al.. (2020). Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Advances. 4(23). 5951–5957. 17 indexed citations

Vannata, Barbara, Anna Vanazzi, Sarah Liptrott, et al.. (2020). A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas. Hematological Oncology. 39(1). 60–65. 2 indexed citations

Cocorocchio, Emilia, Anna Vanazzi, Sebastián Bassi, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 4. 184–184. 2 indexed citations

10.

Vanazzi, Anna, Chiara Maria Grana, C. Crosta, et al.. (2013). Efficacy of⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. Hematological Oncology. 32(1). 10–15. 17 indexed citations

11.

Andreola, Giovanna, Anna Vanazzi, Davide Radice, et al.. (2012). Who should be really considered as a poor mobilizer in the plerixafor era?. Transfusion and Apheresis Science. 47(1). 27–32. 8 indexed citations

12.

Saini, Kamal S., Hatem A. Azim, Emilia Cocorocchio, et al.. (2010). Rituximab in Hodgkin lymphoma: Is the target always a hit?. Cancer Treatment Reviews. 37(5). 385–390. 30 indexed citations

13.

Grana, Chiara Maria, Anna Vanazzi, Mahila Ferrari, et al.. (2009). The Role of Dosimetry in the High Activity ⁹⁰ Y-Ibritumomab Tiuxetan Regimens: Two Cases of Abnormal Biodistribution. Cancer Biotherapy and Radiopharmaceuticals. 24(2). 271–275. 7 indexed citations

14.

Cocorocchio, Emilia, Anna Vanazzi, Edoardo Botteri, et al.. (2009). Prognostic role of interim ¹⁸FDG-PET in Hodgkin lymphoma: A single-center experience. Journal of Clinical Oncology. 27(15_suppl). e19520–e19520. 2 indexed citations

15.

Laszlò, Daniele, Giancarlo Pruneri, Giovanna Andreola, et al.. (2009). Tissue Microarrays in Diffuse Large B-Cell Lymphomas. International Journal of Surgical Pathology. 19(4). 417–424. 2 indexed citations

16.

Trovato, Cristina, Angelica Sonzogni, D. Ravizza, et al.. (2008). Confocal laser endomicroscopy diagnosis of gastric adenocarcinoma in a patient treated for gastric diffuse large-B-cell lymphoma. Digestive and Liver Disease. 41(6). 447–449. 6 indexed citations

17.

Cremonesi, Marta, Mahila Ferrari, Chiara Maria Grana, et al.. (2007). High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment. Journal of Nuclear Medicine. 48(11). 1871–1879. 36 indexed citations

18.

Ferrucci, Pier Francesco, Anna Vanazzi, Chiara Maria Grana, et al.. (2007). High activity ⁹⁰Y‐ibritumomab tiuxetan (Zevalin^®) with peripheral blood progenitor cells support in patients with refractory/resistant B‐cell non‐Hodgkin lymphomas. British Journal of Haematology. 139(4). 590–599. 33 indexed citations

19.

Vanazzi, Anna, Pier Francesco Ferrucci, Chiara Maria Grana, et al.. (2006). Efficacy of 90Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma.. Blood. 108(11). 2771–2771. 2 indexed citations

20.

Martinelli, Giovanni, Daniele Laszlò, Francesco Bertolini, et al.. (2003). Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non‐Hodgkin's lymphoma. British Journal of Haematology. 123(2). 271–277. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact